Novocure (NASDAQ: NVCR) reported Q2 EPS of ($0.48), $0.11 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $17.9 million versus the consensus estimate of $15.9 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.